An integrated bioanalytical method development and validation approach: Case studies

Biomedical Chromatography

Volumn 26, Issue 10, 2012, Pages 1215-1227

  Xue, Y J ^a   Melo, Brian ^a   Vallejo, Martha ^a   Zhao, Yuwen ^b   Tang, Lina ^b   Chen, Yuan Shek ^b   Keller, Karin M ^c  

^a CELGENE CORPORATION   (United States)

^b Translational Medicine Department   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Bioanalytical method; LC MS MS; Matrix effects; Ruggedness; Stability

Indexed keywords

CONTROLLED DRUG DELIVERY; FAILURE ANALYSIS; RATS; SCREENING;

BIOANALYTICAL METHODS; DEVELOPMENT APPROACH; INCURRED SAMPLES; LC-MS-MS; LC.MS/MS; MATRICES EFFECT; METHOD DEVELOPMENT; METHOD VALIDATIONS; RAT PLASMA; RUGGEDNESS;

QUALITY CONTROL;

ACCURACY; ANALYTIC METHOD; ANIMAL TISSUE; ARTICLE; BIOANALYTICAL METHOD; BLOOD ANALYSIS; CHEMICAL COMPOSITION; COLUMN CHROMATOGRAPHY; EXPERIMENTAL DOG; EXTRACTION; LIQUID CHROMATOGRAPHY; METABOLISM; NONHUMAN; PROCESS DEVELOPMENT; QUALITY CONTROL; RAT; STORAGE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CANIS FAMILIARIS; RATTUS;

EID: 84865793926     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2682     Document Type: Article

References (22)

1. Eeckhaut AV, Lanckmans K, Sarre S, Smolders I and Michotte Y. Validation of bioanalytical LC-MS/MS assays: evaluation of matrix effects. Journal of Chromatography B 2009; 877: 2198-2207.
2. Fast DM, Kelley M, Viswanathan CT, O'Shaughnessy J, Peter King S, Chaudhary A, Weiner R, DeStefano AJ and Tang D. Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. The AAPS Journal, 2009; 11: 238-241.
3. Fura A, Harper TW, Zhang H, Fung L and Shyu WC. Shift in pH of biological fluids during storage and processing: effect on bioanalysis. Journal of Pharmaceutical and Biomedical Analysis 2003; 32: 513-522.
4. Heller DN. Ruggedness testing of quantitative atmospheric pressure ionization mass spectrometry methods: the effect of co-injected matrix on matrix effects. Rapid Communications in Mass Spectrometry 2007; 21: 644-652.
5. James CA and Hill HM. Procedural elements involved in maintaining bioanalytical data integrity for good laboratory practices studies and regulated clinical studies. The AAPS Journal 2007; 9: E123-E127.
6. Jemal M and Xia YQ. LC-MS development stratergies for quantitative bioanalysis. Current Drug Metabolism 2006; 7: 491-502.
7. Jemal M, Ouyang Z and Xia YQ. Systematic LC-MS/MS bioanalytical method development that incorporates plasma phospholipids risk avoidance, usage of incurred sample and well throught-out chromatography. Biomedical Chromatography 2010; 24: 2-19.
8. Koitka M, Höchel J, Gieschen H and Borchert H. Improving the ex vivo stability of drug ester compounds in rat and dog serum: inhibition of the specific esterases and implications on their identity. Journal of Pharmaceutical and Biomedical Analysis 2010; 51: 664-678.
9. Larger PJ, Breda M, Fraier D, Hughes H and James CA. Ion-suppression effects in liquid chromatography-tandem mass spectrometry due to a formulation agent, a case study in drug discovery bioanalysis. Journal of Pharmaceutical and Biomedical Analysis 2005; 39: 206-216.
10. Liu G, Snapp HM, Ji QC and Arnold ME. Strategy of accelerated method development for high-throughput bioanalytical assays using ultra high-performance liquid chromatography coupled with mass spectrometry. Analytical Chemistry 2009; 81: 9225-9232.
11. Matuszewski BK. Standard line slopes as a measure of a relative matrix effect in quantitative HPLC-MS bioanalysis. Journal of Chromatography B 2006; 830: 293-300.
12. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at pictogram per milliliter concentrations. Analytical Chemistry 1998; 70: 882-889.
13. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
14. Mei H, Hsieh Y, Nardo C, Xu X, Wang S, Ng K and Korfmacher WA. Investigation of matrix effects in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to drug discovery. Rapid Communications in Mass Spectrometry 2003; 17: 97-103.
15. Nowatzke W and Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. The AAPS Journal 2007; 9: E117-E122.
16. Rocci Jr. ML, Devanarayan V, Haughey DB and Jardieu P. Confirmatory reanalysis of incurred bioanalytical analysis. The AAPS Journal 2007; 9: E336-E343.
17. US Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for drug Evaluation and Research: Rockville, MD, 2001.
18. Venn RF. Principle and Practice of Bioanalysis, 2nd edn. CRC Press: New York, 2008; chapter 1.
19. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstas J, Shah VP, Skelly JP, Swann PG and Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research 2007; 24: 1962-1973.
20. Xu RN, Fan L, Rieser MJ and El-Shourbagy TA. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2007; 44: 342-355.
21. Xue YJ, Akinsanya JB, Liu J and Unger SE. A simplified protein precipitation/mixed-mode cation-exchange solid-phase extraction, followed by high-speed liquid chromatography/mass spectrometry, for the determination of a basic drug in human plasma. Rapid Communications in Mass Spectrometry 2006a; 20: 2660-2668.
22. Xue YJ, Liu J and Unger SE. A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of muraglitazar in human plasma. Journal of Pharmaceutical and Biomedical Analysis 2006b; 41: 979-988.